Incidence of childhood acute lymphoblastic leukemia (ALL) and population-based treatment results in Switzerland: Experiences with 507 study and 149 nonstudy patients
✍ Scribed by Stupnicki, A. ;von der Weid, N. ;Imbach, P. ;Arnet, B. ;Berchtold, W. ;Delaleu, B. ;Hirt, A. ;Pluess, H. J. ;Beck, D. ;Wyss, M. ;Luethy, A. Ridolfi ;Feldges, A. ;Signer, E. ;Morin, A. M. ;Caflisch, U. ;Leibundgut, K. ;Frey, E. ;Kuechler, H. ;Baumgartner, C. ;Bleher, E. A. ;Angst, R. ;Blauenstein, U. ;Nobile, L. ;Vischer, D. ;Wagner, H. P.
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 389 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Of 656 patients with ALL (all types) diagnosed in Switzerland during 4 consecutive 4‐year periods (1976–1979, 1980–1983, 1984–1987, 1988–1991), 507 were officially registered on protocols (“study” patients) while 149 were not (“nonstudy” patients). The mean incidence of 3.8/100,000 children <15 years/year is higher than reported for other Western countries. Evidence is presented suggesting that the 656 patients represent only approximately 90% of all children with ALL residing in Switzerland, indicating that the true incidence of ALL might even be higher. The fraction of “nonstudy” patients fell from 40% (1976–1979) to 15% (1984–1987). The rate of survival at 4 years of all patients with ALL (“study” and “nonstudy”) increased by 17% during the three consecutive periods 1976–1979, 1980–1983, and 1984–1987. As expected, a higher increase (20%) was observed in “study” patients and a statistically nonsignificant lower one (10%) in “nonstudy” patients. © 1995 Wiley‐Liss, Inc.